Developing a test to help treat leukaemia that has spread to the brain
Developing leukaemic biomarkers to enable personalised CNS-directed therapy
Improving our understanding of ependymomas in the spinal cord
Comprehensive molecular characterization of paediatric spinal ependymomas
Repurposing mebendazole and albendazole for acute myeloid leukaemia
Testing the use of mebendazole and albendazole for children with acute myeloid leukaemia, and investigating how the drugs work.
Developing a blood test to help identify high risk Wilms tumours
Circulating molecular biomarkers for earlier identification of high risk Wilms tumour
Improving treatment and reducing side effects for children with B-cell NHL
Identification of new drug targets to improve treatment options and reduce treatment-related toxicity for children diagnosed with aggressive B-cell non-Hodgkin lymphoma (B-NHL)
Discovering biomarkers in high grade glioma to help find targeted treatments
Identifying the metabolic ‘Achilles Heel’ of childhood brain cancers
How do childhood brain tumours start?
Defining the cellular origins of neonatal and paediatric brain tumours
Investigating a new way of delivery drugs to the site of childhood brain tumours
Brain distribution models to select polymer-delivered drugs for the treatment of childhood brain cancers
Can a carbohydrate restricted diet help treat childhood brain tumours?
In vitro evaluation of the potential of glucose restriction as an adjuvant therapy for paediatric brain tumours